Bilateral Salpingo-Oophorectomy Beneficial in BRCA1/2 Carriers With Personal History of Breast Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, May 13, 2025 -- For carriers of pathogenic variants in BRCA1 and BRCA2 with a personal history of breast cancer, bilateral salpingo-oophorectomy (BSO) is beneficial, resulting in a reduced risk for all-cause mortality and breast cancer-specific mortality, according to a study published online May 7 in The Lancet Oncology.
Hend Hassan, from the University of Cambridge in the United Kingdom, and colleagues examined the association between BSO and long-term health outcomes in women aged 20 to 75 years carrying pathogenic variants in BRCA1 and BRCA2 and with a personal history of breast cancer. The analyses used data from the National Cancer Registration Dataset and the Hospital Episode Statistics-Admitted Patient Care dataset, and included 1,674 BRCA1, 1,740 BRCA2, and nine BRCA1 and BRCA2 carriers who were diagnosed with breast cancer between 1995 and 2019.
The researchers found that uptake of BSO was significantly lower among Black and Asian versus White women (odds ratios, 0.48 and 0.47, respectively). Women living in the least socioeconomically deprived areas had higher BSO uptake (odds ratio, 1.38 versus most deprived). For both BRCA1 and BRCA2 pathogenic variant carriers, BSO was associated with a reduced risk for all-cause mortality (hazard ratio, 0.52) and with reduced breast cancer-specific mortality (hazard ratios, 0.62 and 0.48 for BRCA1 and BRCA2, respectively). In the combined BRCA1 and BRCA2 sample, BSO was also associated with a reduced risk for a second non-breast cancer (hazard ratio, 0.59). In the combined sample, BSO was not associated with an increased risk for cardiovascular diseases, ischemic heart disease, cerebrovascular disease, non-breast cancer-specific mortality, contralateral breast cancer, or depression.
“Our findings will be crucial for counseling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation,” senior study author Antonis Antoniou, Ph.D., also from the University of Cambridge, said in a press release.
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Nearly Half With Early-Stage Breast Cancer Extend Endocrine Therapy Beyond Five Years
FRIDAY, June 20, 2025 -- Nearly 40 percent of women with stage I breast cancer and two-thirds with stage II decide to extend endocrine therapy, according to a study published...
More Than One in 10 Surgical Patients Face Food Insecurity
FRIDAY, June 20, 2025 -- Food insecurity is a significant burden among U.S. surgical patients, according to a study published online June 18 in JAMA Surgery. Annabelle...
New Model Developed for Identifying DVT in Epithelial Ovarian Cancer
TUESDAY, June 17, 2025 -- A model with eight independent risk factors can predict the risk for deep vein thrombosis (DVT) in patients with epithelial ovarian cancer (EOC)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.